FORM NAMCS-CCS

U.S. DEPARTMENT OF COMMERCE
Economics and Statistics Administration
U.S. CENSUS BUREAU
ACTING AS DATA COLLECTION AGENT FOR THE

ACTING AS DATA COLLECTION AGENT FOR THE
U.S. Department of Health and Human Services
Centers for Disease Control and Prevention
National Center for Health Statistics

NATIONAL AMBULATORY MEDICAL CARE SURVEY 2010 CERVICAL CANCER SCREENING SUPPLEMENT

NOTICE – Public reporting burden of this collection of information is estimated to average 20 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: CDC/ATSDR Information Collection Review Office, 1600 Clifton Road, MS D-74, Atlanta, GA 30333, ATTN: PRA(0920-0234).

Assurance of Confidentiality – All information which would permit identification of any individual, a practice, or an establishment will be held confidential, will be used for statistical purposes only by NCHS staff, contractors, and agents only when required and with necessary controls, and will not be disclosed or released to other persons without the consent of the individual or the establishment in accordance with section 308(d) of the Public Health Service Act (42 USC 242m) and the Confidential Information Protection and Statistical Efficiency Act (PL-107-347).

242m) and the Confidential Information Protection and Statistical Efficiency Act (PL-	-107-347).					
BACKGROUND	INFORMATION					
BACKGROUND INFORMATION A. Provider's specialty (Mark (X) only ONE.) 1 General/Family 2 Internal 3 OB/ 4 CHC Mid-level Practice Medicine GYN Provider B. Census contact name						
C. Provider's serial number	D. Census contact telepho	Area code Number				
The Centers for Disease Control and F screening performed in community heaf following questions. We appreciate you	alth centers and p ur time on this im	rivate offi portant p	ce setting	s. Please th conce	e answer rn.	the
 Does your practice use any of the following methods to scree cervical cancer? Mark (X) all that apply. Conventional Pap test (Definition – Smear spread on glass slice) 	de and fixed)	Annually	Eveny 2	Every 3 years	More than 3 years	No routine interval recom- mended
1 ☐ Yes – How often does your practice routinely screen wom using this method? 2 ☐ No 3 ☐ Unknown 3 ☐ Unknown	1 1 I	2	3 🗆	4 🗆	5 🗆	
b. Liquid-based cytology (Definition – Specimen suspended in liquidate) 1 Yes – How often does your practice routinely screen women using this method? 2 No 3 Unknown Continue with item 1c	 1	2	3□	4	5 🗆	
• Other – Specify 1 ☐ Yes – How often does your practice routinely screen wom	nen using	 				
this method? 2 No 3 Unknown	→	1	2	3 🗆	4	5
2. Does your practice perform colposcopy? 1 Yes 2 No 3 Unknown						

Does your practice ever order or collect the Human Papillomavirus (HPV) DNA test? 1 Yes - Go to item 3b 2 No - SKIP to item 3c 3 Not aware of HPV DNA test 4 Unknown SKIP to item 9 on page 4 Which of the following HPV DNA tests are ordered or	4a.	If a patient's Pap test result is borderline or abnormal, does your practice routinely order an HPV DNA test to be performed on that sample (commonly called reflex HPV DNA testing)? (An HPV DNA test may be run on the same liquid-based medium as the Pap test or an HPV DNA test specimen may be collected at the same time as the conventional Pap test.) 1 Yes – Go to item 4b				
collected in your practice? Mark (X) all that apply. 1 High risk (HR) HPV DNA test 2 Low risk (LR) HPV DNA test 3 Not aware there was a high risk or low risk HPV DNA test 4 Type-specific HPV DNA test	b.	SKIP to item 5a SKIP to item 5a For which borderline or abnormal Pap test result would your practice order or collect a reflex HPV DNA test? Mark (X) all that apply.				
Why is the HPV DNA test not ordered or collected in your practice? − <i>Mark</i> (<i>X</i>) all that apply. 1 My practice does not see the types of patients for whom the HPV DNA test is indicated. 2 My practice uses other tests, procedures, or examination methods to manage patients for whom the HPV DNA test is indicated. 3 The patients in my practice have timely access to		ASC-US (atypical squamous cells of undetermined significance) ASC-H (atypical squamous cells of undetermined significance − cannot exclude high-grade intraepithelial lesion) LSIL (low-grade squamous intraepithelial lesion, encompassing mild dysplasia/CIN1) HSIL (high-grade squamous intraepithelial lesion, moderate dysplasia/CIN2, severe dysplasia/CIN3, and carcinoma in situ) AGC (atypical glandular cells)				
colposcopy. 4 Assessing patients' HPV infection status is not a priority at my practice. 5 The labs affiliated with my practice do not offer the HPV DNA test. 6 The health plans or health systems affiliated with my practice do not recommend the HPV DNA test. 7 The HPV DNA test is not a reimbursed or covered service for most patients in my practice.		For which patients does your practice usually order reflet HPV DNA testing? − Mark (X) all that apply. 1 Women under 21 years old 2 Women 21 years old to 29 years old 3 Women 30 years old and over 4 Other − Specify ✓				
 Discussing cervical cancer screening in the context of an STD is avoided in my practice. Notifying or counseling patients about positive HPV DNA test results would take too much time. Notifying or counseling patients about positive HPV DNA test results might make clinicians in my practice feel uncomfortable. Notifying or counseling patients about positive HPV DNA test results might make patients in my practice feel uncomfortable, angry, or upset. SKIP to item 7 on page 3. 		Does your practice routinely recall patients to come back for a second sample collection for an HPV DNA test if their Pap test is abnormal or borderline (recall testing)? 1 Yes – Go to item 5b 2 No 3 Unknown SKIP to item 6a on page 3 For which abnormal or borderline Pap test result would your practice recall a patient for an HPV DNA test? Mark (X) all that apply. ASC-US (atypical squamous cells of undetermined significance) ASC-H (atypical squamous cells of undetermined significance – cannot exclude high-grade intraepithelial lesion) LSIL (low-grade squamous intraepithelial lesion, encompassing mild dysplasic (CIN1)				
		encompassing mild dysplasia/CIN1) 4 HSIL (high-grade squamous intraepithelial lesion, moderate dysplasia/CIN2, severe dysplasia/CIN3, and carcinoma in situ) 5 AGC (atypical glandular cells)				

Page 2 FORM NAMCS-CCS (10-8-2009)

6a.	Does your practice routinely order or collect an HPV DNA test at the same time as the Pap test as part of routine cervical cancer screening (commonly called adjunct HPV testing or cotesting)?										
	1 ☐ Yes – Go to item 6b										
	2 ☐ No 3 ☐ Unknown } SKIP to item 7										
b.	For which patients does your practice routinely order or collect an HPV DNA test along with the Pap test (commonly called adjunct HPV testing or cotesting)? Mark (X) all that apply.										
	women under 21 years old women 21 years old to 29 years old women 30 years old and over women who request the test for cervical cancer screening women who request the test to check their HPV infection status women who request the test to check their HPV infection status										
7.		ren the following scre years of age return				ur practice r	ecommend the	nat a woma	an between	30 and	
			l		For eac	ch of the fo	llowing scen	arios, mar	k (X) only	ONE for ea	ch row.
	in pa (exclu	ap test results st 5 years uding current nal results)	Current HPV DNA test results	Current Pap test result	No follow-up needed	Less than 6 months	6 months to less than 1 year	1 year	2 years	3 years or more	Have no experience with this type of patient or test
	(a)	Two consecutive normal Pap tests	Has not had test	Normal	1	2	з 🗆	4	5 🗌	6 🗆	7 🗆
	(b)	Two consecutive normal Pap tests	 Negative 	Normal	1	2	3 🗌	4	5 🗌	6	7 🗌
	(c)	Two consecutive normal Pap tests	 Positive	Normal	1	2	3 🗆	4 🗌	5 🗌	6	7 🗌
	(d)	Has not had a Pap test	 Negative	Normal	1	2	3 🗆	4 🗌	5	6	7 🗌
	(e)	Has not had a Pap test	Positive	Normal	1	2	3 🗆	4 🗌	5	6	7 🗌
	(f)	Abnormal Pap test	 Negative 	Normal	1	2	3 🗌	4 🗌	5	6	7 🗌
	(g)	Abnormal Pap test	Positive	Normal	1	2	3 🗌	4	5	6	7 🗌
			QU	ESTIONS	8-14 AS	K ABOUT	THE HPV V	ACCINE			
8.											
	1 ☐ Rarely or never 2 ☐ Sometimes 3 ☐ Usually 4 ☐ Always or almost always 5 ☐ Do not recommend the HPV vaccine −SKIP to item 10.										

FORM NAMCS-CCS (10-8-2009) Page 3

9.	As it relates to the HPV vaccine,								
	how often does your practice –	Rarely or	Sometimes	Hayally	Always or almost	Unknown/Not applicable/			
	Mark (X) only ONE for each row.	never	Sometimes	Usually	always	applicable/ Do not ask			
	a. Use the number of sexual partners to determine who should get the HPV vaccine?	1 🗆	2	3 🗆	4 🗆	5			
	b. Perform a Pap test to determine who should get the HPV vaccine?	1	2	з 🗌	4	5 🗌			
	c. Recommend the HPV vaccine to females with a history of an abnormal Pap test result (ASC-US or higher)?	1	2	з 🗆	4 🗌	5 🗌			
	d. Recommend the HPV vaccine to females with a positive HPV test?	1 🗌	2	з 🗌	4 🗌	5 🗌			
10.	Will your practice's cervical cancer screening management procedures change for females been fully vaccinated with the HPV vaccine?	1 Yes 2 No − <i>SKIP to</i>	item 14						
11.	How will your practice determine when to state cervical cancer screening for fully HPV vaccifemales?	vaccinate	age as non-HPV ed females –						
	Mark (X) all that apply.		Specify age———→						
			2 ☐ At a later age —						
		į	Specify a	_					
		2□ By onset of sexual activity – How many year(s) since							
		onset of sexual activity?——→ 3 □ Will not be screening fully HPV vaccinated females							
		4 Unknown							
12.	How often will your practice routinely screen	_							
	cancer among females that have been fully v	vaccinated 2 Every 2-3 years							
	with the HPV vaccine? <i>Mark (X) one.</i>	1	3 Every 4–5 years						
			4□ Greater than every 5 years 5□ Will not be screening fully HPV vaccinated females						
			6 Unknown						
13.	Will your practice be using the HPV DNA test for managing abnormal cytology for females that have been fully vaccinated with the HPV vaccine?								
14.	Please indicate to what extent you agree, diswith each statement. Please respond to both	unsure	Agree	Disagree	Unsure				
	There will be fewer numbers of abnormal Pap tests among vaccinated females.			1 🗆	2	з□			
	b. There will be fewer referrals for colpose vaccinated females.	1 🗆	2	з□					
15.	The Centers for Disease Control and Prevention (CDC) funds state health departments to provide breast and cervical cancer screening services to low income women through the National Breast and Cervical Cancer Early Detection Program (Title XV). The state health departments contract out the screening services to physicians and other health care providers. Is this practice currently participating in this state or national screening program? 1 Yes 2 No 3 Unknown								
16.	For purposes of this survey, which of the following categories describe your profession? - Mark (X) only ONE.								
	1 ☐ Physician 2 ☐ Physician assistant/ 3 ☐ Registered nurse 4 ☐ Other office staff Nurse practitioner/ Nurse midwife								

CLOSING STATEMENT

Thank you for completing this special survey. We appreciate your time and cooperation.

Page 4 FORM NAMCS-CCS (10-8-2009)